Merck starts pivotal Phase 2b/3 MALBEC trial of MK-8748 for wet AMD

Reuters04-02
Merck starts pivotal Phase 2b/3 MALBEC trial of MK-8748 for wet <a href="https://laohu8.com/S/AMD">AMD</a>
  • Merck initiated pivotal Phase 2b/3 MALBEC trial for MK-8748 (Tiespectus) in neovascular age-related macular degeneration.
  • Decision follows results already presented from Phase 1/2a RIOJA trial, which supported moving drug into late-stage development.
  • Program targets longer-lasting control of retinal vascular leakage, aiming to reduce risk of further vision loss versus current options.
  • Second late-stage study in neovascular age-related macular degeneration is scheduled to begin this year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604020650BIZWIRE_USPR_____20260401_BW721827) on April 02, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment